Impact of ICCAN on Cancer Treatment Completion and Quality of Life

Participant Inclusion Criteria:

Patient is eligible if he/she is

• fluent in English, Spanish, or Mandarin

• between the ages of 21-80 years old

• cancer patients currently receiving chemotherapy (started within the past month)and/or radiation therapy (started within the past week), or

• scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)

• planning on remaining in the area for at least 1 year

Clinician is eligible if he/she:

• Has an MD or DO degree

• Is the treating physician providing care to a patient enrolled to the study

ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:

• Is 18 - 85 years of age

• Has unresectable locally advanced, locally recurrent unresectable, metastatic, orhigh risk/early stage TNBC or stage I-IV lung cancer

• Eligible for FDA approved immunotherapy in the NYC metropolitan area (perself-report or per MSK patient EMR records).

• Is treated in the NY metropolitan area

• Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined ashousehold income < 200% of federal poverty level)

• Has English or Spanish proficiency

• Agrees to be audio-recorded

ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report:

• Is 18 - 85 years of age

• Has stage II-III TNBC

• Treated at MSK Manhattan or OneMSK regional sites

• Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined ashousehold income < 200% of federal poverty level)

• Has English or Spanish proficiency

• Agrees to be audio-recorded

ICCAN-IO process evaluation study team participants only:

• Staff member who serves as an Access Facilitator

• Agrees to be audio-recorded

Participant Exclusion Criteria:

Patient is ineligible is he/she is:

• Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms whichrequire individual treatment) and/or cognitive impairment disorder (e.g., deliriumor dementia) verified by medical record sufficient to preclude completion of theassessment measures, interview or informed consent

ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:

• Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptomswhich require individual treatment) and/or cognitive impairment disorder (e.g.,delirium or dementia) sufficient to preclude completion of the assessment measures,interview or informed consent

• Participants or family members who are participating in MSK IHCD studies related tosocial determinants of health

ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:

• Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms whichrequire individual treatment) and/or cognitive impairment disorder (e.g., deliriumor dementia) sufficient to preclude completion of the assessment measures, interviewor informed consent

• Participants or family members who are participating in MSK IHCD studies related tosocial determinants of health